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TrIE aim of the present study was to investigate the pos-
sible effect of platelet-activating factor (PAF), by com-
parison with interleukin-l and polyriboinositic/
polyribocytidylic (poly I--C) acid, on 11-6 production by L
929 mouse flbroblasts. At concentrations above 1 gtM PAF,
the production of 11-6 by mouse flbroblasts was
enhanced in a dose dependent fashion. At 5 tM PAF, the
peak increase (60.1 + 19.4 U/ml) was similar to that
induced by 50 tg/ml poly I--C (60.0 + 35.0 U/ml) and
higher than the one evoked by 100 U/ml IL-I[ (3.8 + 1.8
U/ml). The increase of 11-6 activity induced by 5 tM PAF
was maximal after a 22 h incubation period with L 929
cells. Lyso-PAF (5 ttM) also increased 11-6 activity from
flbroblasts to a similar extent compared with 5 tM PAF.
In addition, the 11-6 activity induced by 5 tM PAFwas still
observed when the specific PAF antagonist, BN 52021 (10
ttM), was added to the incubation medium of L 929 cells.
The result suggests that the production of 11-6 by L 929
cells evoked by PAF in vitro is not receptor mediated. The
in vivo effect of PAF on 11-6 production was also investi-
gated in the rat. Two hours after intravenous injection of
PAF (2 to 4 tg/kg), a dramatic increase of 11-6 activity in
rat serumwas observed, this effect being dose dependent.
The increase of 11-6 induced by 3 Ixg/kg PAF was not
observed when the animals were treated with the PAF
antagonist, BN 52021 (1 to 60 mg/kg0. These results dem-
onstrate that PAF modulates 11-6 production and that the
in vivo effect is receptor mediated.
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Introduction
A T cell line derived, B cell differentiation factor (B
cell stimulatory factor-2) has been identified in both
human and mouse. This protein has been shown to
be identical to fibroblast derived interferon-[,. (IFN-
[2)3,4 and has been referred to as interleukin-6 (IL-6).
This cytokine is produced by a wide variety of cell
types and demonstrates many biological effects, both
in vitro and in vivo. Although its primary source
appears to be the monocyte/macrophage,7,8 IL-6 is
also induced in human and murine fibroblasts on
stimulation with IL-1 and tumour necrosis factor
(TNF)o 4,9 Biological activities of IL-6 include induction
of acute phase protein synthesis by hepatocytes,
1
stimulation of immunoglobulin synthesis by B cells,
increase of T lymphocyte responses, 11,12 and prolif-
eration of multi-potential haematopoietic progenitors
in synergy with IL-3.13
It has been demonstrated previously that the
phospholipid mediator, PAF modulates the produc-
tion of the monocyte/macrophage derived cytokine,
IL-1, both in vitro4 and in vivo.5 Indeed, this lipid
mediator either increases or decreases IL-1 activity in
cell supernatants from. lipopolysaccharide (LPS)
stimulated rat macrophages according to the dose
and the time period of addition. As accessory cells
produce both IL-11 and IL-6, the question arose
whether PAF could also modulate the in vitro and in
vivo production of IL-6.
Materials and Methods
Reagents: The double-stranded RNA, polyribo-
inosinic/polyribocytidylic (poly I-C) and bovine
serum albumin (BSA) were purchased from Sigma
(St Louis, MO, USA). IL-I was obtained from TEBU
(Les Ulis, France). IL-6 was obtained from Immu-
genex (Los Angeles, CA, USA). Fibroblasts were
cultured in DMEM (Flow Laboratories, Virginia, USA)
containing 10% foetal bovine serum (FBS, Gibco,
Paisley, UK). In the in vitro experiments, BN 52021
(IHB Research Laboratories, Le Plessis Robinson,
France) was dissolved in dimethylsulfoxide (DMSO)
at the 10 mM concentration and further diluted in.a
10rnM HEPES solution. For the in vivo experiments
the drugs were dissolved in physiological serum
containing 0.25% BSA. PAF (C16-PAF) and lyso-PAF
were obtained from Novabiochem (Clery en vexin,
France).
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Cell cultures: The mouse embryonic fibroblast cell
line, L 929, was cultured in DMEM containing 10%
FBS. The cells (2.5 x 105/10 mD were incubated at
37C in multi-well dishes for about I week, i.e. a time
period at which the cells reach confluence. At the
end of this incubation period, the medium was
removed and 5 ml of fresh medium was added.
Various substances, namely It-l13, poly I-C, lyso-
PAF, PAF, BN 52021 or.the vehicle of PAF, i.e. DMEM
containing 0.25% BSA, or DMSO, were added at
defined concentrations or dilutions. In some experi-
ments, after incubation at 37C for 4 h to 48 h as
specified, the cell suspensions were centrifuged at
400 xg for 10 min and the supernatants were col-
lected and stored at -20C prior to assay for IL-6
activity. No effect of the solvent of PAF or DMSO on
the IL-6 release was noted (data not shown). In some
experiments, the release of lactate dehydrogenase
(LDH) was assessed using commercial kits from
Boehringer (Mannheim, Germany).
In vivo experiments: Sprague-Dawley rats (250 g)
were injected intravenously with either PAF or lyso-
PAF and blood samples were obtained after 1, 2, 3,
4, 6 and 24 h. In some experiments, BN 52021 or
solvent alone was injected intraperitoneally 30 min
prior to the injection of PAF or vehicle.
Bioassay ofIL-6:IL-6 activity in cell-free supernatants
from mouse fibroblasts or rat serum was measured by
the proliferation of the 7DT1 cell line (obtained
through the courtesy of Dr J. van Snick, Brussels,
Belgium). Briefly, triplicates of 2 x 103 cells in 0.2 ml
were added with defined dilutions of the
supematants or sera to be tested. Appropriate control
media or known amounts of rIL-6 were also in-
cluded. In some experiments, the anti-iL-6 antibody,
6B4 (obtained through the courtesy of Dr J. Van
Snick, Brussels, Belgium), was added to supematants
from L 929 for 30 min prior to the assessment of
IL-6 activity. After defined incubation periods, the
number of viable cells was evaluated by the
colorimetric determination of the levels of [3-
hexosaminidase. The data are expressed as means +
S.E.M. of the indicated number of experiments and
the results were assessed for statistical significance
using the analysis of variance. Results are either
expressed in optical density (OD) or in equivalent
U/ml of recombinant IL-6 (rlL-6), with respect to the
linear portion of calibration curves performed with
known amounts of the recombinant cytokine.
In a preliminary experiment, as measured by the
colorimetric determination of ]3-hexosaminidase, the
proliferation of 7TD1 was.shown to be dependent on
both the dose of rIL-6 and the incubation period. A
minimal cell proliferation, although not dose related,
was observed after 48 h. After 72 h, the increase in
the [3-hexosaminidase content of the cells was related
to IL-6 concentration and reached plateau values
after 96 h. At this later time period, a dose related
effect was noted in the range, of concentrations from
0.01 U/ml to 5 U/ml rlL-6 (data not shown), a plateau
being reached for concentrations above 5 U/ml.
Since a maximal increase in the -hexosaminidase
content was noted after 96 h, this time period was
used to assess the IL-6 activity in the various
supernatants.
Results
Effect ofPAFon IL-6production by L 929 cells: When
L 929 cells were incubated for 48 h at 37C in medium
alone, low IL-6 activity was measured in the
supernatants. A 96 h incubation period was demon-
strated previously to be optimal for the production of
IL-6 by this cell type and was thus used.8 The activity
in the supernatants of unstimulated L 929 cells de-
creased with the dilution from 1/2 to 1/256 (data not
shown). When the results are expressed in U/ml,
L 929 cells produced 1.3 _+ 0.7 U/ml. Addition of
IL-l[3 (100 U/ml) to L 929 cultures increased the
IL-6 section, although not to a significant level at the
1/2 dilution or below the 1/8 one. In contrast, when
the supernatants were measured at 1/4 and 1/8
dilutions, IL-1]3 significantly enhanced the IL-6
production by 102% and 96%, respectively (data not
shown). Poly I-C (50 ILtg/ml) markedly increased
IL-6 production with a higher efficiency compared
with IL-113 (Fig. 1). In a preliminary set of experi-
ments, the effect of the phospholipid mediator, PAF,
was compared with one of the two agonists and
shown to enhance markedly the IL-6 production
from L 929 cells at the 5 I.tM concentration (Fig. 1).
Lower concentrations of PAF were also used (1 I.tM
to 10 fM), but no effect on IL-6 production was
noted.
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FIG. 1. IL-6 activity in supernatants from cultured L 929 cells incubated with
various agonists. Fibroblasts (1 week old) were cultured in the presence or
absence of IL-11 (100 U/ml), poly I-C (50 Ig/ml) or PAF (1 IM and 5 IM)
for 48 at 37C. At the end of the culture pedod, the supernatants were
collected and assayed for IL-6 activity, as measured by the colorimetric
determination of -hexosaminidase which reflects the proliferation of 7TD1
cells. Results are expressed in equivalent U/ml of recombinant IL-6 calcu-
lated from a standard curve established with known amounts of this
cytokine and as means S.E.M. of four experiments. *p < 0.05; **p < 0.01.
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The IL-6 activity in the various supernatants was
calculated as equivalent U/ml with respect to calibra-
tion curves performed with known amounts of rlL-6.
When the results are expressed in U/ml, PAF at the
5 t.tM concentration and poly I-C at the 50 l.tg/ml, a
marked release of IL-6 from L 929 fibroblasts (60.1 +
19.4 U/ml) and (60.0 _+ 35 U/ml), respectively, was
induced compared with 100 U/ml IL-I[ (3.8 -+ 1.8 U/
ml). In contrast, 1 lttM PAF had no significant effect
(2.9 _+ 1.4 U/ml) on IL-6 production compared with
unstimulated L 929 cells (1.3 _+ 0.7 U/ml) (Fig. 1).
The kinetics of released and cell associated IL-6
activity upon stimulation of L 929 with 5 l.tM PAF and
poly I-C (100 lttg/ml) were then investigated. The
spontaneous IL-6 activity was shown to be signifi-
cantly increased after 22 h, 28 h and 48 h, compared
with the value measured after 4 h. A significant
enhancement of the released IL-6 activity by PAF was
observed after 22 h and up to 48 h following stimu-
lation of L 929 cells, compared with the spontaneous
production of this cytokine (Fig. 2). By comparison,
poly I-C increased the released IL-6 activity as early
as 4 h after addition of this agonist and up to 48 h.
Neither, PAF nor poly I-C significantly modified cell
associated IL-6 activity above basal level (0.099+_
0.010 OD unit). To determine whether the activity
inducing the proliferation of 7TD1 was indeed due
to IL-6, supernatants and cell associated activity from
L 929 cells stimulated or not with PAF or poly I-C
were collected at defined time intervals and incu-
bated with the anti-IL-6 antibody (1/160 dilution) for
30 min prior to adding to 7TD1 cells for 96 h. The
optical density measured at the end of the 96 h
incubation period in supernatants when the anti-
IL-6 antibody was added, was identical to the one
observed upon incubation of 7TD1 in the absence
of IL-6 (0.063 _+ 0.012, OD unit, i.e. < 0.4 U/ml,
n= 7).
The number of cells alive counted with trypan blue
was identical after treatment with PAF and poly I-C
compared with unstimulated L 929 cells (Table 1),
indicating that the increase of IL-6 activity in
supernatants of PAF or poly I-C stimulated cells was
not due to a cytotoxic effect of these compounds. In
addition, the lack of cell cytoxicity of 5 gtM PAF was
confirmed by the measurement of lactate
dehydrogenase (LDH) in supernatants. In contrast,
100 gtg/ml poly I-C was toxic for L 929 cells after
48 h in culture (115.2 + 28.8 U/ml LDH compared
with 54.5 + 15.1 U/ml in controls).
In the next series of experiments, the dose de-
pendent effect of PAF (1 tM to 5 l.tM) on the release
of IL-6 activity from L 929 cells was investigated after
48 h. A dose related increase in IL-6 activity in the
supernatants of cells stimulated with concentrations
of PAF above 1 laM was indeed observed (Fig. 3).
Addition of the anti-IL-6 antibody to supernatants
from unstimulated and PAF stimulated L 929 cells
inhibited by 84 to 90% the proliferation of 7TD1 cells
(Fig. 3).
The specificity of the effect of PAF on the release
of IL-6 activity from L 929 was investigated next. No
specificity was observed in this in vitro model using
mouse fibroblasts. Indeed, a similar IL-6 activity after
48 h incubation of L 929 cells with 5 I.tM lyso-PAF or
5 I.tM PAF was noted. When the results were cal-
culated as equivalent units, lyso-PAF and PAF
produced after 48 h 77.1 +_ 36.5 U/ml and 66.1 +_
17.0 U/ml IL-6, respectively, compared with unstimu-
lated L 929 cells (2.0 _+ 0.7 U/ml). Supernatants
from L 929 cells treated with lyso-PAF and PAF
incubated with anti-IL-6 antibody did not exhibit
significant IL-6 activity (97% inhibition). In addition,
BN 52021 (101.tM) did not interfere with the
enhancing effect ofPAF on the IL-6 activity produced
by L 929 cells after 48 h (data not shown).
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FIG. 2. Kinetics of the released IL-6 activity after incubation of L 929 cells
with various agonists. Fibroblasts (1 week old) were cultured in the pres-
ence or absence of poly I--C (100 tCg/ml) or PAF (5 IM) for 4, 22, 28 and
48 h at 37C. At each indicated time point, the supernatants were collected
and assayed for IL-6 activity. In these experiments the supernatants were
analysed at the 114 dilution. Results are expressed as O.D. units and as
means S.E.M. of four experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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FIG. 3. Dose dependent effect of PAF on IL-6 production by L 929 cells. IL-
6 activity in supernatants from L 929 cells incubated with defined concen-
trations of PAF. Fibroblasts (1 week old) were cultured in the presence or
in the absence of PAF (1 IM to 5 p.M) for 48 h at 37C. At the end of the
culture period, the supernatants were collected, the monoclonal antibody
(mAb) directed against IL-6 added or not as appropriate, and assayed for
IL-6 activity. In these experiments the supernatants were analysed at the
114 dilution. Results are expressed as O.D. and as means S.E.M. of five
experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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Table 1. Time dependent effect of incubation of L 929 cells in the presence of poly I-C and
PAF on cell viability
Cell number (106/ml)
4 h 22 h 28 h 48 h
L 929 8.5 +/- 0.9 7.6 +/- 0.5 8.7 +/- 1.5 10.7 +/- 1.3
Poly I-C (100 lg/ml) 7.1 +/- 0.5 8.1 +/- 1.0 9.9 +/- 1.1 10.9 +/- 1.2
PAF (5 IM) 8.9 +/- 1.0 7.8 +/- 1.0 10.3 +/- 1.4 12.4 +/- 1.9
Fibroblasts (1 week old) were cultured in the presence or absence of poly I-C (100 g/
ml) or PAF (5 M) for 4, 22, 28 and 48 h at 37C. At each indicated time point, the number
of cells alive was determined after addition of trypan blue. Results are expressed as means
+/- S.E.M. of four experiments.
Effect ofPAF on IL-6 levels in rat serum: Intravenous
injection of lyso-PAF at 2 and 3 l.tg/kg did not modify
the level of IL-6 in rat serum after 1 h to 24 h (Fig.
4). In contrast, the IL-6 level was markedly increased
in a dose dependent fashion when rats were treated
with PAF at doses ranging from 2 to 4 l.tg/kg and with
a peak effect observed 2 h after injection (Fig. 4).
Indeed, treatment with 2, 3 and 4 t.tg/kg PAF in-
creased by 44-, 63- and 73-fold the level of IL-6 in rat
serum, respectively. However, intravenous injection
of PAF at 4 l.tg/kg was toxic, since half of the rats died
during the first hour of experimentation. Although
the maximum increase obtained after 2 h was of
lower intensity with 3 l.tg/kg PAF compared with
4 g/kg, this dose of PAF and this time period
were chosen for further experiments investigating
the effect of BN 52021 on the in vivo IL-6 pro-
duction.
Intraperitoneal injection of BN 52021 at 0.1, 1, 5
and 15 mg/kg was performed 30 min before intra-
venous injection of 3 lttg/kg PAF or vehicle alone.
No effect of treatment of the animals with BN 52021
on the basal level of IL-6 measured at 2 h was
noted. When the rats were treated with the dose of
1, 5 or 15 mg/kg BN 52021, the peak of IL-6 in
serum observed 2 h following intravenous injection
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FIG. 4. Effect of intravenous injection of various compounds in rats.
Sprague-Dawley rats (250 g) were injected intravenously with PAF or lyso-
PAF and blood samples were obtained after defined time intervals. IL-6 in
sera was determined as described in the Materials and Methods section.
Results are expressed in equivalent U/m111-6 and as means S.E.M. of the
three to five experiments.
of 3 t.tg/kg PAF was not observed (p < 0.001,
Fig. 5). By contrast, the dose of 0.1 mg/kg was
inefficient in preventing the PAF induced increase in
IL-6 levels in rat serum.
In a second series of experiments, the possibility
that treatment of the rat with BN 52021 delayed the
appearance of IL-6 in serum was investigated. In
these experiments, only the 15 mg/kg dose of BN
52021 was investigated. As presented in Fig. 6, no IL-
6 activity in serum was detected at all time points of
this kinetic study.
Discussion
In the present study, it is confirmed that the
fibroblast cell line, L 929, produces IL-6-1ike activity
and that this production is enhanced by IL-I and to
a greater extent by poly I-C, PAF and lyso-PAF.
IL-lJ is already known as one of the physiologic in-
ducers of IL-6 by fibroblasts. The double-stranded
RNA, poly I-C, has also been shown to induce IL-6,
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FIG. 5. Effect of BN 52021 on the in vivo production of IL-6 by PAF.
Sprague-Dawley rats (250 g) were injected intravenously with PAF (3 g/
kg) or solvent of PAF. The animals were treated or not with BN 52021 (0.1
to 15 mg/kg) or vehicle 30 min prior to injection of PAF. Blood samples were
obtained after 2 h and IL-6 in sera was determined as described in the
Materials and Methods section. The results are expressed in equivalent U/
ml IL-6 and as means $.E.M. of the three to six experiments. ***p < 0.001.
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FIG. 6. Kinetic of the effect of BN 52021 on the in vivo production of IL-6
by PAF. Sprague-Dawley rats (250 g) were injected intravenously with PAF
(3 lg/kg) or solvent of PAF. The animals were treated or not with BN 52021
(15 mg/kg) or vehicle 30 min prior to injection of PAF. Blood samples were
obtained after a defined time interval and IL-6 in sera was determined as
described in the Materials and Methods section. The results are expressed
in equivalent U/ml IL-6 and as means S.E.M. of the three to five experi-
ments. *p < 0.05; ***p < 0.001.
although more efficiently compared with IL-I. The
results presented here demonstrate that L 929 cells
stimulated with PAF or lyso-PAF produced high
IL-6-1ike activity. The increase in IL-6 activity
observed with lyso-PAF is puzzling and could be due
to the presence of acetyl-CoA: 1-0-alkyl-sn-glyceryl-
3-phosphorylcholine acetyltransferase in fibroblasts.
However, this hypothesis, was not investigated in the
present study. Alternatively, the possibility that lyso-
PAF evokes IL-6 independently of the stimulation of
a specific receptor is also open.
The fact that 10 ILtM BN 52021 did not inhibit the
IL-6 production induced by 5 l.tM PAF was unex-
pected, although this lack of effect of this PAF an-
tagonist might be due to an unfavourable antagonist/
agonist ratio (2:1, on a molar basis). Higher doses of
BN 52021 could not be investigated due to the toxic
effect of the vehicle (DMSO) of this drug on L 929
cells. These results, as well as the induction of IL-6
release by lyso-PAF, indicate that the action of PAF
could be unrelated to the stimulation of PAF specific
receptors. The possibility that lyso-PAF could be the
agonist implicated in the induction of IL-6 in L 929
cells is under investigation.
High levels of circulating IL-6 have been observed
in various inflammatory states such as widespread
burnsTM and septic shock. 19 Injection of PAF in rats
evokes a dramatic increase in IL-6 activity in serum.
The in vivo effect of PAF appears to be mediated via
specific binding sites because BN 52021 prevents the
PAF induced increase in IL-6 production. In addition,
administration of lyso-PAF in rats is inefficient in
inducing IL-6 production, further strengthening the
specificity of the effect of PAF.
The present data demonstrate that PAF might play
an in vivo immunoregulatory role via an increase of
IL-6 level in serum. In fibroblasts, IL-6 appears to be
an autocrine factor2,21 and the release of this cytokine
in response to mediators elaborated in areas of tissue
damage may contribute to the local inflammatory
response. These data support the concept that PAF is
not only a mediator of acute allergic and inflamma-
tory reactions but might also contribute to long-term
processes such as chronic diseases.
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